文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 临床医学 > Zagouri 2015 Fulvestrant and male breast cancer
侵权投诉

Zagouri 2015 Fulvestrant and male breast cancer

BreastCancerResTreat(2015)149:269–275DOI10.1007/s10549-014-3240-z

EPIDEMIOLOGY

Fulvestrantandmalebreastcancer:apooledanalysis

FloraZagouri TheodorosN.Sergentanis

DimosthenisChrysikos Meletios-AthanasiosDimopoulosTheodoraPsaltopoulou

Received:10November2014/Accepted:10December2014/Publishedonline:18December2014ÓSpringerScience+BusinessMediaNewYork2014

AbstractMalebreastcancerisanuncommonmalig-nancy;littleisknownregardinghormonalmanipulationsfortamoxifen-resistantmalebreastcancerpatients.Thisisthe rstpooledanalysisoftheliteraturetosynthesizeallavailabledataandtoevaluatetheef cacyandsafetyoffulvestrantinmalebreastcancer.Thisstudywasper-formedinaccordancewiththePRISMAguidelines.Allstudiesthatexaminedtheef cacyoffulvestrantinmalebreastcancer,regardlessofsamplesize,wereconsideredeligible.Thesearchstrategyretrieved31articles;ofthese, vearticleswereeligible(23patients)forthispooledanalysis.Themeanageofthestudysamplewas63.1years.Adjuvanthormonaltreatmentwasadministeredin87.5%ofcases.Fulvestrantwasgivenas rstorsecondlinein40%ofpatients,whileasthirdlineorbeyondin60%ofpatients.79.0%ofpatientsatfulvestrantadministrationhadvisceralmetastases.Regardingbestresponse,in26.1%PRwasachieved,in47.8%ofcasesSDwasrecorded,whereasin26.1%ofpatientsPDwasnoted.ThemedianPFSwasequalto5months.Nograde3and4adverseeventswererecorded;ofnote,hot asheswerereportedin18.2%ofmalebreastcancerpatients.Fulve-strantmaypotentiallyplayapromisingroleintheoptimaltherapeuticstrategyformalepatientswithbreastcancerdiagnosis.However,furtherclinicalandpharmacokinetic

investigationsaremorethanwarrantedbeforefulvestrantusebecomesacommonpracticeinmalebreastcancerpatients.

KeywordsMalebreastcancerÁFulvestantÁHormonaltreatmentÁTherapyÁPooledanalysis

Introduction

Malebreastcancerisanuncommonmalignancyanditaccountsapproximatelyforlessthanonepercentofalldiagnosedbreastcancers[1].Duetotherarityofthedis-easeinmen,clinical-trialreportsarelackingandconse-quently,treatmentrecommendationsinmenaremainlyextrapolatedfromtheresultsoftrialsinwomen.Accordingtocurrentclinicalguidelines,tamoxifenisthegoldstan-dardintheadjuvantendocrinetherapyofmalebreastcancerandplaysaputativeroleinthemetastaticsetting[2–4].However,littleisknownregardinghormonalmanipulationsfortamoxifen-resistantmalebreastcancerpatients.

Fulvestrantisapureestrogenreceptor(ER)antagonistorselectiveERdown-regulator;itbindscompetitivelytoERsinbreastcancercells,leadingtoERdeformationanddecreasedbindingofestrogen[5].AfterphaseIIItrials,thatdemonstratedsimilaref cacyalongwithanacceptablesafetypro leforfulvestrant250mgcom-paredwithanastrozole,aswellassubsequenttrialsevaluatingfulvestrant250versus500mg,currentlyful-vestrant500mghasbeenapprovedastreatmentinpostmenopausalwomenwithadvancedhormonerecep-tor-positivebreastcancerwhohadprogressedorrecurredafterpriorantiestrogentherapy(tamoxifenand/orAI)[6,7].Thereisnoprospectiveclinicaltrialwiththeuse

F.Zagouri(&)ÁD.ChrysikosÁM.-A.Dimopoulos

DepartmentofClinicalTherapeutics,MedicalSchool,AlexandraHospital,UniversityofAthens,VasSo asAve&Louroustr,11521Athens,Greece

e-mail: orazagouri@yahoo.co.uk

T.N.SergentanisÁT.Psaltopoulou

DepartmentofHygiene,EpidemiologyandMedicalStatistics,MedicalSchool,UniversityofAthens,Athens,Greece

123

第1页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email